Laurus Labs Ltd
Healthcare | Mid Cap
Laurus Labs Ltd. presents a mixed but generally positive financial profile. The company's greatest strengths are its exceptional profitability, outstanding growth prospects, and rock-solid financial structure. It has very low levels of debt, meaning it is not burdened by large interest payments and has a stable long-term foundation. Projections indicate a massive rebound in revenue and profits, suggesting that a recent downturn was a temporary event. However, the company faces significant challenges in its operational efficiency. It takes a very long time to sell its products and collect payments from customers, which ties up cash and can strain day-to-day finances. This is also reflected in its tight liquidity position, with limited cash immediately available to cover short-term expenses. Overall, it's a highly profitable and fast-growing company with a strong balance sheet, but its operational and cash management processes are areas of weakness.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio6.40
- Profitability Ratio10.00
- Efficiency Ratio2.33
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio3.58
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
Laurus Labs Ltd. presents a mixed but generally positive financial profile. The company's greatest strengths are its exceptional profitability, outstanding growth prospects, and rock-solid financial structure. It has very low levels of debt, meaning it is not burdened by large interest payments and has a stable long-term foundation. Projections indicate a massive rebound in revenue and profits, suggesting that a recent downturn was a temporary event. However, the company faces significant challenges in its operational efficiency. It takes a very long time to sell its products and collect payments from customers, which ties up cash and can strain day-to-day finances. This is also reflected in its tight liquidity position, with limited cash immediately available to cover short-term expenses. Overall, it's a highly profitable and fast-growing company with a strong balance sheet, but its operational and cash management processes are areas of weakness.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
102.98
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
85.84
P/B RATIO
14.39
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
10.89
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
0.00
EV/EBITDA RATIO
40.82
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1412.9 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤5th May 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤30th Apr 26
Audited Consolidated Financial Results for the Year Ended March 31, 2026
BULLISH SENTIMENT
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
The company's growth outlook is exceptionally strong. Despite a significant contraction in the most recent fiscal year, the weighted average and forward-looking estimates project a powerful and rapid recovery. Strong growth is anticipated across revenue, operating profit, and net income. This suggests that the market and analysts view the recent challenges as temporary and expect the company to return to a high-growth trajectory, underpinned by consistent expansion of its asset base to support future business.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 2.53 | 22.39 | -16.55 | 10.18 | 22.67 |
| Operating Profit Growth Rate | -8.25 | 11.8 | -51.07 | 35.43 | 68.53 |
| Earnings Per Share (EPS) Growth | -15.98 | -4.74 | -79.69 | 122.82 | 147.89 |
| Asset Growth Rate | 21.16 | 9.93 | 9.49 | 11.32 | 12.59 |
| Net Income Growth Rate | -15.45 | -4.69 | -79.57 | 120.99 | 148.6 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed but generally positive view for investors. It generates very strong cash earnings per share and has a solid, growing book value, which builds shareholder wealth. However, the dividend paid out to shareholders is relatively low. A key point is the high level of capital expenditure in recent years, which has consumed cash. This spending is projected to decrease, which could positively impact future cash flows and shareholder returns. The projected rebound in adjusted EPS is a strong positive signal.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 15.66 | 14.74 | 3.06 | 5.91 | 16.5 |
| Cash Earnings Per Share (Cash EPS) | 20.24 | 20.69 | 10.13 | 14.59 | 25.37 |
| Book Value Per Share | 62.64 | 74.78 | 76.13 | 82.83 | 98.15 |
| Dividend Per Share (DPS) | 2 | 2.05 | 0.8 | 1.2 | 1.15 |
| Capital Expenditures (CapEx) | 877 | 987 | 676 | 541 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability profile is excellent. It consistently demonstrates a strong ability to generate returns for its shareholders and on the capital it employs. Across various metrics, from operating margins to return on assets, the company shows robust performance. This high level of profitability indicates efficient cost management and a strong market position for its products and services. Despite a dip in the most recent year, the overall historical and projected figures confirm that profitability is a core strength of the business.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.76 | 20.99 | 7.82 | 11.25 | 19.05 |
| Return on Capital Employed (ROCE) | 26 | 23 | 7 | 9 | 18 |
| Return on Equity (ROE) | 24.83 | 19.64 | 3.94 | 8 | 16.79 |
| Return on Assets (ROA) | 20.44 | 20.78 | 9.29 | 11.3 | 16.92 |
| Operating Margin | 28.85 | 26.35 | 15.45 | 19 | 26.1 |
| Net Margin | 16.86 | 13.13 | 3.21 | 6.45 | 13.06 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency is a notable area of weakness. The analysis shows that it is slow in converting its assets, particularly inventory and receivables, into sales and cash. It takes a considerable amount of time to sell its products and even longer to collect the money owed by customers. This inefficiency ties up a significant amount of capital in the business cycle, restricting cash flow and indicating that assets are not being used to their full potential to generate revenue.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.86 | 1.77 | 1.3 | 1.35 | 1.56 |
| Inventory Turnover Ratio | 2.26 | 2.77 | 2.63 | 2.61 | 2.58 |
| Receivables Turnover Ratio | 3.71 | 4.12 | 3.11 | 3.03 | 3.27 |
| Days Sales in Inventory Ratio | 161.5 | 131.77 | 138.78 | 139.85 | 141.47 |
| Receivable Days | 98.38 | 88.59 | 117.36 | 120.46 | 111.62 |
| Capital Turnover Ratio | 1.24 | 1.25 | 1.01 | 1.07 | 1.13 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is excellent. Its operating earnings provide a very substantial cushion to meet its interest payments, indicating a low risk of default on its debt. Furthermore, its profits are more than sufficient to cover its dividend payments to shareholders, suggesting that the dividend is very secure. This strong coverage reflects a healthy and low-risk financial position, providing confidence to both lenders and investors.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 11.63 | 7.72 | 2.29 | 3.24 | 7.91 |
| Equity Dividend Coverage Ratio | 7.69 | 7.14 | 3.7 | 5.56 | 14.29 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits an exceptionally strong solvency position, indicating a very low risk of long-term financial distress. It finances its operations predominantly through equity rather than debt, resulting in a healthy and stable balance sheet. This low reliance on borrowing means the company is well-insulated from risks associated with rising interest rates and has significant flexibility for future financing if needed. This conservative financial structure is a major strength, providing a secure foundation for sustainable growth and stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.16 | 0.17 | 0.17 | 0.14 | 0.12 |
| Debt to Equity Ratio | 0.19 | 0.2 | 0.2 | 0.16 | 0.14 |
| Equity Ratio | 0.84 | 0.83 | 0.83 | 0.86 | 0.88 |
| Debt To Asset Ratio | 0.09 | 0.1 | 0.1 | 0.08 | 0.07 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position indicates a tight capacity to meet its short-term financial obligations. While it has enough current assets to cover current liabilities, its reserves of cash and near-cash assets are very low. This means the company is heavily reliant on selling its inventory and collecting payments from customers in a timely manner to pay its bills. A delay in either of these activities could create financial pressure. The cash generated from its core business operations is also modest compared to its short-term debts, reinforcing this dependency on working capital.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.17 | 1.3 | 1.16 | 1.09 | 1.13 |
| Quick Ratio | 0.58 | 0.7 | 0.62 | 0.62 | 0.61 |
| Cash Ratio | 0.03 | 0.02 | 0.04 | 0.03 | 0.03 |
| Operating Cash Flow Ratio | 0.31 | 0.35 | 0.2 | 0.15 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.89 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.91 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 9 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 13 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
Management effectiveness is assessed as weak. The company exhibits a severe deterioration in financial performance, highlighted by a sharp decline in sales, profits, and operating margins in the most recent fiscal year. Capital efficiency metrics such as ROCE have plummeted, indicating unproductive use of capital. Financial health is strained by rising debt levels and a significantly weakened interest coverage ratio. While increasing institutional ownership suggests some external confidence in a potential turnaround, this is heavily outweighed by the low promoter holding and the breadth of negative performance indicators across the board. The overall picture is one of significant operational and financial stress.
Financial Performance & Growth
The company's financial performance has deteriorated significantly. After a period of strong growth, annual sales growth turned negative at -16.6% in FY2024. This indicates a major challenge in revenue generation. The impact on profitability has been more severe, with net profit declining by 80% in FY2024. This follows a period of high growth, but the recent trend shows extreme volatility and a sharp downturn. Operating Profit Margin (OPM) has also contracted from an average of 29% between FY21-23 to just 15% in FY2024, reflecting pressures on operational efficiency and cost structures. The inconsistency in both top-line and bottom-line performance points to significant business headwinds and operational challenges.
| Metric | 2015–2017 Avg | 2018–2020 Avg | 2021–2023 Avg | 2024 |
|---|---|---|---|---|
| Sales Growth (%) | 18.5% | 14.3% | 31.6% | -16.6% |
| OPM (%) | 19% | 19% | 29% | 15% |
| Profit Growth (%) | 36.3% | 38.3% | 88.0% | -80.0% |
Capital Efficiency & Returns
Capital efficiency and returns have collapsed, indicating poor management of the company's capital base. Return on Capital Employed (ROCE) has plummeted from a strong average of 29.7% in the FY21-23 period to a mere 7% in FY2024. This drastic fall suggests that the capital invested in the business is no longer generating productive returns. The efficiency of working capital management has also worsened. The Cash Conversion Cycle (CCC), which measures the time taken to convert investments in inventory and other resources into cash, has elongated to 240 days in FY2024. This is a deterioration from previous periods and ties up more cash in operations, signaling inefficiency in managing receivables and inventory, especially during a period of declining sales.
| Metric | 2015–2017 Avg | 2018–2020 Avg | 2021–2023 Avg | 2024 |
|---|---|---|---|---|
| ROCE (%) | 15.3% | 12.0% | 29.7% | 7.0% |
| Cash Conversion Cycle (Days) | 188 | 181 | 212 | 240 |
Financial Health & Prudence
The company's financial health shows signs of stress. Borrowings have steadily increased, reaching ₹2,577 Cr in FY2024, up from an average of ₹1,758 Cr in the preceding three years. Concurrently, the Debt-to-Equity ratio has risen to 0.63. While this level of debt may not be alarming in isolation, it is a concern when coupled with collapsing profitability. The Interest Coverage Ratio (ICR) has sharply declined from a very comfortable average of 15.5x between FY21-23 to just 4.3x in FY2024. This rapid deterioration reflects a significantly diminished capacity to service debt obligations from operating profits. This combination of rising debt and falling profit coverage points to weak financial prudence.
| Metric | 2015–2017 Avg | 2018–2020 Avg | 2021–2023 Avg | 2024 |
|---|---|---|---|---|
| Borrowings (₹ Cr) | 941 | 1,032 | 1,758 | 2,577 |
| Interest Coverage Ratio | 3.1x | 5.2x | 15.5x | 4.3x |
Shareholding & Ownership Structure
The ownership structure presents a mixed picture. A significant weakness is the promoter holding, which stands at a relatively low 27.18% as of March 2024. This stake has also seen a gradual decline from 32.04% in March 2020. A low and decreasing promoter holding can raise concerns about alignment with minority shareholders. In contrast, a notable strength is the growing confidence from institutional investors. Foreign Institutional Investor (FII) holding has consistently increased, reaching 25.98% in March 2024 from 20.68% three years prior. Similarly, Domestic Institutional Investor (DII) holding has also risen significantly to 11.78% from 3.56% over the same period. This strong and increasing institutional ownership indicates that large, sophisticated investors see value or a turnaround potential in the company.
| Holder (%) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Promoter | 27.45% | 27.27% | 27.20% | 27.18% |
| FII | 20.68% | 22.45% | 22.42% | 25.98% |
| DII | 3.56% | 7.93% | 9.74% | 11.78% |
The overall risk profile is high. The primary risks stem from deteriorating financial health and potential accounting pressures. The company's profitability has collapsed, leading to a sharp drop in its ability to cover interest payments, a significant risk given its rising debt levels. This exposes the company to financial distress if interest rates rise or if profits remain depressed. Additionally, erratic movements in working capital metrics, such as a high Cash Conversion Cycle and fluctuating Days Payable, combined with negative free cash flow in the latest year, suggest potential liquidity strain and aggressive cash management practices. The existing financial trajectory presents substantial operational and financial risk.
Accounting quality and liquidity
Several metrics suggest potential accounting quality and liquidity risks. The Cash Conversion Cycle has remained elevated at 240 days, indicating that a significant amount of cash is tied up in operations. The 'Days Payable' metric has been erratic, swinging from 146 days in FY22 to 94 in FY23, and then sharply up to 158 in FY24, which can indicate inconsistent working capital management. Most critically, the company reported a negative Free Cash Flow (FCF) of -₹10 Cr in FY2024, a deterioration from a small positive FCF in prior years. Generating negative cash flow during a period of falling profits is a significant red flag for liquidity. The dividend payout ratio of 27% despite an 80% profit drop also points to cash management priorities that are not aligned with conserving capital.
Interest rate exposure
The company faces significant exposure to interest rate risk. Total borrowings have increased by 28% in the last year alone, while operating profit has halved. This has caused the Interest Coverage Ratio to collapse from 9.7x to 4.3x. This sharp decline means a much smaller portion of operating profit is available to cover interest expenses, making earnings highly sensitive to any further increase in interest rates or a continuation of poor performance. With a lower buffer, any adverse movement in borrowing costs could directly and materially impact the company's net profitability and its ability to service its debt, elevating financial risk.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101395.60Bullish
- SMA 201379.32Bullish
- SMA 501383.80Bullish
- EMA 101399.61Bullish
- EMA 201389.27Bullish
- EMA 501387.12Bullish
- DEMA 101414.91Bearish
- DEMA 201399.27Bullish
- DEMA 501384.60Bullish
- TEMA 101421.26Bearish
- TEMA 201412.25Bearish
- TEMA 501381.51Bullish
- MACD9.35Bullish
- ADX26.70Strong Trend
- IndicatorValueSignal
- RSI65.21Neutral
- CCI113.96Overbought
- ROC 93.97Bullish
- ROC 143.16Bullish
- ROC 253.29Bullish
- Stoch K85.30Overbought
- Stoch D90.31Overbought
- IndicatorValueSignal
- BB Upper1424.63Neutral
- BB Middle1379.32Neutral
- BB Lower1334.01Neutral
- ATR12.38Low Volatility
- IndicatorValueSignal
- MFI63.64Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101384.75Bullish
- SMA 201379.99Bullish
- SMA 501399.50Bullish
- EMA 101392.95Bullish
- EMA 201387.73Bullish
- EMA 501385.68Bullish
- DEMA 101405.01Bullish
- DEMA 201388.99Bullish
- DEMA 501399.80Bullish
- TEMA 101415.73Bearish
- TEMA 201396.43Bullish
- TEMA 501379.23Bullish
- MACD2.96Bullish
- ADX22.94Weak Trend
- IndicatorValueSignal
- RSI59.59Neutral
- CCI130.89Overbought
- ROC 93.04Bullish
- ROC 144.85Bullish
- ROC 251.47Bullish
- Stoch K89.43Overbought
- Stoch D88.52Overbought
- IndicatorValueSignal
- BB Upper1420.40Neutral
- BB Middle1379.98Neutral
- BB Lower1339.57Neutral
- ATR17.88Low Volatility
- IndicatorValueSignal
- MFI72.77Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101379.84Bullish
- SMA 201391.66Bullish
- SMA 501379.05Bullish
- EMA 101388.25Bullish
- EMA 201387.46Bullish
- EMA 501355.76Bullish
- DEMA 101390.65Bullish
- DEMA 201392.24Bullish
- DEMA 501434.27Bearish
- TEMA 101398.00Bullish
- TEMA 201380.37Bullish
- TEMA 50N/AN/A
- MACD3.24Bearish
- ADX23.59Weak Trend
- IndicatorValueSignal
- RSI57.38Neutral
- CCI87.21Neutral
- ROC 91.56Bullish
- ROC 141.59Bullish
- ROC 251.20Bullish
- Stoch K73.35Neutral
- Stoch D50.40Neutral
- IndicatorValueSignal
- BB Upper1436.27Neutral
- BB Middle1391.66Neutral
- BB Lower1347.06Neutral
- ATR27.07Low Volatility
- IndicatorValueSignal
- MFI58.38Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101395.08Bearish
- SMA 201385.59Bearish
- SMA 501258.74Bullish
- SMA 1001133.10Bullish
- SMA 2001050.83Bullish
- EMA 101383.34Bearish
- EMA 201366.78Bullish
- EMA 501279.16Bullish
- EMA 1001183.15Bullish
- EMA 2001061.83Bullish
- DEMA 101384.27Bearish
- DEMA 201417.66Bearish
- DEMA 501404.13Bearish
- DEMA 1001332.11Bullish
- DEMA 2001266.53Bullish
- TEMA 101366.91Bullish
- TEMA 201396.63Bearish
- TEMA 501445.83Bearish
- TEMA 1001382.13Bearish
- TEMA 2001320.08Bullish
- MACD33.08Bearish
- ADX36.23Strong Trend
- IndicatorValueSignal
- RSI55.75Neutral
- CCI-63.95Neutral
- ROC 140.50Bullish
- ROC 256.90Bullish
- Stoch K25.21Neutral
- Stoch D29.93Neutral
- IndicatorValueSignal
- BB Upper1436.00Neutral
- BB Middle1385.59Neutral
- BB Lower1335.17Neutral
- ATR36.03Low Volatility
- IndicatorValueSignal
- MFI47.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 201130.08Bullish
- SMA 501012.08Bullish
- EMA 201182.85Bullish
- EMA 501019.49Bullish
- DEMA 201322.14Bullish
- DEMA 501234.18Bullish
- TEMA 201371.09Bullish
- TEMA 501296.06Bullish
- MACD111.74Bullish
- ADX37.26Strong Trend
- IndicatorValueSignal
- RSI71.13Overbought
- CCI235.71Overbought
- ROC 1435.87Bullish
- ROC 2533.40Bullish
- Stoch K93.48Overbought
- Stoch D94.56Overbought
- IndicatorValueSignal
- BB Upper1443.14Neutral
- BB Middle1130.08Neutral
- BB Lower817.02Neutral
- ATR74.79High Volatility
- IndicatorValueSignal
- MFI69.58Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 61100.74Bullish
- SMA 12990.61Bullish
- SMA 24762.86Bullish
- EMA 61118.34Bullish
- EMA 12995.97Bullish
- EMA 24833.86Bullish
- DEMA 61238.93Bullish
- DEMA 121189.79Bullish
- DEMA 241068.44Bullish
- TEMA 61264.85Bullish
- TEMA 121238.65Bullish
- TEMA 241179.17Bullish
- MACD215.91Bullish
- ADX47.68Strong Trend
- IndicatorValueSignal
- RSI72.24Overbought
- CCI245.09Overbought
- ROC 25202.67Bullish
- ROC 50130.81Bullish
- Stoch K90.02Overbought
- Stoch D86.44Overbought
- IndicatorValueSignal
- BB Upper1302.29Overbought
- BB Middle824.33Neutral
- BB Lower346.37Neutral
- ATR126.66High Volatility
- IndicatorValueSignal
- MFI84.56Overbought